
Opinion|Videos|July 29, 2024
Out of Pocket Costs Associated with Biosimilar Use
The panel discusses out of pocket costs and the impact of the 340b program for various patient types.
Advertisement
Episodes in this series

Newsletter
Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on AJMC
1
Advancing Early Detection and Equitable Access in Alzheimer Disease Care
2
Digital Innovation and New Drugs Converge to Transform CRM Care
3
Bills to Address Expiring ACA Subsidies Fail to Pass Senate
4
Blinatumomab Boosts Survival in Pediatric ALL, but Faces Delivery Hurdles
5








































